Testing effectiveness (Phase 2)Study completedNCT00083694What this trial is testingThalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory LeukemiaWho this might be right forLeukemia University of Arkansas 25
Not applicableStudy completedNCT04872621What this trial is testingCalquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient InvestigationWho this might be right forRelapsed or Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Lymphoma) AstraZeneca 104
Testing effectiveness (Phase 2)Study completedNCT01116193What this trial is testingRepeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic LeukemiaWho this might be right forLeukemia, LymphoidPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma Institut de Cancérologie de la Loire 10
Testing effectiveness (Phase 2)UnknownNCT04714593What this trial is testingTargeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic LeukemiaWho this might be right forAcute Lymphocytic Leukemia， B-Cell Shanxi Province Cancer Hospital 24
Testing effectiveness (Phase 2)Study completedNCT01314014What this trial is testingImexon for Relapsed Follicular and Aggressive LymphomasWho this might be right forFollicular LymphomaSmall Lymphocytic LymphomaMarginal Zone Lymphoma+4 more University of Rochester 22
Not applicableStudy completedNCT00281814What this trial is testingCaregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow TransplantWho this might be right forChronic Myeloproliferative DisordersLeukemiaLymphoma+4 more The Cleveland Clinic 36
Early research (Phase 1)WithdrawnNCT03807063What this trial is testingRivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell TransplantWho this might be right forAcute Bilineal LeukemiaMyelodysplastic/Myeloproliferative NeoplasmMyelodysplastic/Myeloproliferative Neoplasm, Unclassifiable+9 more Fred Hutchinson Cancer Center
Large-scale testing (Phase 3)Looking for participantsNCT07516093What this trial is testingStudy of NX-5948 Versus Pirtobrutinib in R/R CLL/SLLWho this might be right forB-cell LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma Nurix Therapeutics, Inc. 620
Testing effectiveness (Phase 2)Ended earlyNCT05405309What this trial is testingRP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic LeukemiaWho this might be right forChronic Lymphocytic Leukemia University of Utah 5
Early research (Phase 1)Looking for participantsNCT06466395What this trial is testingA Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated LeukemiasWho this might be right forRefractory Acute LeukemiaRelapsed Acute LeukemiaUndifferentiated Leukemia+1 more M.D. Anderson Cancer Center 22
Early research (Phase 1)Active Not RecruitingNCT02935257What this trial is testingImmunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19Who this might be right forLeukemia, Lymphoblastic, Acute, Lymphoma University College, London 72
Testing effectiveness (Phase 2)Study completedNCT00096096What this trial is testingTacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantationWho this might be right forChronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+4 more Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00723346What this trial is testingAdministration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic LeukaemiaWho this might be right forAcute Lymphoblastic Leukemia ERYtech Pharma 25
Very early researchEnded earlyNCT04034446What this trial is testingCD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)Who this might be right forRelapsed or Refractory B Cell Acute Lymphoblastic Leukemia Institute of Hematology & Blood Diseases Hospital, China 2
Early research (Phase 1)WithdrawnNCT05519527What this trial is testingSTI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL AmyloidosisWho this might be right forRefractory T Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia (AML) M.D. Anderson Cancer Center
Large-scale testing (Phase 3)Study completedNCT03476239What this trial is testingEfficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)Who this might be right forAcute Lymphoblastic Leukemia Amgen 121
Testing effectiveness (Phase 2)UnknownNCT01354457What this trial is testingSafety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+Who this might be right forAcute Lymphoblastic Leukemia Nantes University Hospital 21
Early research (Phase 1)Study completedNCT00005946What this trial is testingChemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell TransplantationWho this might be right forLeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more University of Maryland, Baltimore
Early research (Phase 1)WithdrawnNCT05487495What this trial is testingDonor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/LymphomaWho this might be right forT-Cell Acute Lymphoblastic Leukemia/Lymphoma Beijing Boren Hospital
Testing effectiveness (Phase 2)Study completedNCT01289457What this trial is testingClofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic SyndromeWho this might be right forLeukemia M.D. Anderson Cancer Center 282